首页> 外文期刊>Medical Science Monitor Basic Research >Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth
【24h】

Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth

机译:微渗透泵可在幼年大鼠中持续释放酪氨酸激酶抑制剂博舒替尼及其对骨骼生长的影响

获取原文
           

摘要

Background Bosutinib is a third-generation dual tyrosine kinase inhibitor (TKI) inhibiting Abl and Src kinases. It was developed to act on up-regulated tyrosine kinases (TKs) like BCR-ABL in Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) when resistance to first- and second-generation TKIs developed. However, first- and second-generation TKIs show off-target effects on bone metabolism, whereas studies on skeletal adverse effects of bosutinib are still lacking. Therefore, it was the aim of this study to continuously expose juvenile rats to bosutinib and to analyze its influence on the growing bone. Material and Methods Starting after weaning, 4-week-old Wistar rats were chronically exposed over a 28-day period to varying concentrations of bosutinib, which were continuously administered subcutaneously via implanted Alzet? micro-osmotic pumps. After necropsy, the length of the femora and tibiae were analyzed. Results Continuous administration of bosutinib by micro-osmotic pumps led to serum drug levels in the lower therapeutic range, was well tolerated, and exhibited only minor adverse effects on the growing skeleton. Conclusions Micro-osmotic pumps represent a convenient system for continuous TKI release in young growing rats. Compared to first- and second-generation TKIs, bosutinib seems to exert fewer adverse effects on the growing bone.
机译:背景技术Bosutinib是抑制Abl和Src激酶的第三代双酪氨酸激酶抑制剂(TKI)。当对第一代和第二代TKI产生抗药性时,它可以作用于上调的酪氨酸激酶(TK),如费城染色体阳性(Ph +)慢性髓细胞性白血病(CML)中的BCR-ABL。但是,第一代和第二代TKI对骨骼代谢显示出脱靶效应,而对Bosutinib的骨骼不良作用的研究仍然缺乏。因此,本研究的目的是连续向未成年大鼠暴露于波舒替尼并分析其对骨骼生长的影响。材料和方法从断奶后开始,将4周龄的Wistar大鼠在28天的时间里长期暴露于不同浓度的Bosutinib,并通过植入的Alzet?皮下连续给药。微渗透泵。尸检后,分析股骨和胫骨的长度。结果通过微渗透泵连续给药博舒替尼导致较低治疗范围内的血清药物水平,耐受性良好,并且对生长中的骨骼仅显示较小的不良作用。结论微渗透泵代表了年轻的成年大鼠连续释放TKI的便利系统。与第一代和第二代TKI相比,波舒替尼似乎对生长中的骨骼产生较少的不良影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号